Revenue Catalyst – AI Agents & Revenue Operations for HCLS
Winning HCLS Commercial Teams Are Going Agentic in 2026

AI Agents and Revenue Operations for Healthcare & Life Sciences

Better Intel. More Pipeline. Zero New Headcount.

Built by HCLS operators with deep domain expertise spanning IC to VP across sales, marketing, and customer success – we’ve lived the problems these agents and services solve.

Trust
50+ years of HCLS commercial experience encoded into agent skills and memories
Engine
Frontier-model AI agents transforming real-time signals into actionable intelligence for your team
Validation
Every account, claim, and contact double-verified against public sources
Deliverable
Intel Cards with signals, narratives, contacts, and the hook aligned to your ICP and playbooks
Zero Footprint on Your Systems Agents Get Sharper with Your Feedback First Report in a Week
Get in Touch Services & Pricing
43Qualified Opps in 2.5 Months
56%Cold Email Open Rate
200K+Leads Sequenced Across Clients
90Qualified MQLs in 6 Months
40%YOY Revenue Growth
19.2%Increase in Website Traffic from Campaigns Over 6 Months
266%Traffic Increase in 6 Months
2,400Publication-Matched Leads for a Single Campaign
79%Net New Visitors from 6-Month Campaign
50%Google Ads Cost Reduction
300%Prospecting vs. Goal
16,000Leads Sequenced in a Single Engagement
2 days → 30 minForecasting Time per Territory Manager
43Qualified Opps in 2.5 Months
56%Cold Email Open Rate
200K+Leads Sequenced Across Clients
90Qualified MQLs in 6 Months
40%YOY Revenue Growth
19.2%Increase in Website Traffic from Campaigns Over 6 Months
266%Traffic Increase in 6 Months
2,400Publication-Matched Leads for a Single Campaign
79%Net New Visitors from 6-Month Campaign
50%Google Ads Cost Reduction
300%Prospecting vs. Goal
16,000Leads Sequenced in a Single Engagement
2 days → 30 minForecasting Time per Territory Manager

From Signal to Meeting

Your Autonomous Intelligence Pipeline.

Five AI-powered stages. Aligned to your ICP and playbooks. Tuned by 50+ years of HCLS operator judgement. Sharpens through recursive self-improvement.

Zero Footprint on Your Systems: Managed Intelligence runs entirely on our infrastructure. No IT involvement, no security review, no integrations required – your team just receives the report. For Build + Transfer clients who need full control, we deploy on your VPC or a dedicated single-tenant server with end-to-end encryption.

Intel Cards

Intelligence Your Team Can Act on Today.

Delivered in a tabbed monthly report. Summary, Territory, Leadership, and Deep Dive views with signal narratives, verified contacts, entry angles, and warm introduction paths in each Intel Card.

Summary View

One tabbed report surfaces every signal across your territories in priority order. Filterable by signal type, account, or rep — so leadership and reps start from the same page.

revenue-catalyst-report-april-2026.html
RevenueCatalyst Sales Intelligence Report — April 2026
22 Signals 48 Contacts
Summary
Territory 1
Territory 2
Territory 3
Territory 4
Deep Dive
Expansion Signal Genentech / Roche — $50B U.S. investment, 6+ new sites under construction Full Details ▾
Net-New Prospect Crescent Biopharma — $400M+ Series B, IND cleared Jan 2026 Full Details ▾
Target HCP / KOL Dr. Sarah Chen — VP Translational Medicine, ASCO 2026 Speaker Full Details ▾
Deep Dive Regeneron — Priority account, 14 named personas mapped Full Details ▾
Showing 4 of 22 signals from the Worldwide tab — 48 contacts across all territories
Signal Map
Genentech S. San Francisco, CA Genentech Oceanside, CA Genentech Cambridge, MA Novartis East Hanover, NJ Amgen Thousand Oaks, CA Teva Pharma Kansas City, MO Crescent Bio Waltham, MA BioMarin San Rafael, CA Resilience Cincinnati, OH Veradermics Denver, CO MAIA Bio Chicago, IL ILiAD Bio Rochester, MN Candel Tx Nashville, TN Dr. S. Chen San Diego, CA Meridian Bio Philadelphia, PA MD Anderson Houston, TX
Expansion Net-New HCP / KOL Deep Dive
Expansion Signals
Growth triggers in existing accounts — new facilities, hiring surges, regulatory milestones
Net-New Prospects
Companies not in your CRM that match your ICP — funding rounds, key hires, market entries
Target HCP / KOL
Key opinion leaders and high-value HCPs — publication history, conference activity, connection paths
Deep Dives
Full account dossiers on priority accounts — named personas, competitive landscape, outreach hooks
Territory View

Each rep opens their territory tab and sees expansion signals, net-new prospects, and HCP/KOL targets — each with named contacts and a specific entry angle.

Expansion Signal

Genentech / Roche

South San Francisco, CA
Expansion · XL Hiring · 3 Open Roles Phase 3 Trials
Why Now
$50B U.S. investment announced (Jan 2026). 6+ new sites under construction, Oceanside biologics facility breaking ground Q2 2026. Bispecific antibody portfolio entering late-stage trials. Analytical demand scaling across manufacturing.
Opportunity Size
XL Multi-site expansion, existing install base
Your Play
Your West Coast rep has a direct LinkedIn connection to James Whitfield, who oversees analytical development across Genentech’s South San Francisco campus. With 6 new sites coming online—including Oceanside biologics breaking ground Q2—manufacturing teams are making analytical software decisions now.

Lead with the warm intro: “James, [West Coast Rep] suggested I reach out—your SF team already runs [product] in discovery, and with Oceanside and Cambridge staffing up analytical leads, it might be worth a conversation before PEGS about extending across the new sites.”
Key Contact
James Whitfield, VP, Analytical Development
You ▶ West Coast Rep ▶ J. Whitfield 2nd
LinkedIn •••••• j.whitfield@••••.com IN CRM
Opportunities by Territory
West: South San Francisco (HQ) – 2nd-degree intro via your West Coast rep, platform expansion
West: Oceanside, CA – new biologics manufacturing, breaking ground 2026
East: Cambridge, MA – new clinical biotech hub, hiring analytical leads
Midwest: Vacaville, CA – fill/finish expansion, 2 open LC-MS roles
Global: Basel, Switzerland – Roche parent, central procurement
Net-New Prospect

Crescent Biopharma

Waltham, MA
Series B: $400M+ · Nov 2025 IND Cleared · Jan 2026 Hiring · 3 Analytical Roles
Why Now
IND cleared January 2026 for lead ADC candidate. $400M+ Series B closed November 2025. Building CMC and analytical infrastructure from scratch. No legacy vendor lock-in. Actively hiring analytical scientists.
Opportunity Size
M-L Greenfield build, no incumbent
Your Play
Rachel Torres is building CMC from scratch with no incumbent vendor. Your path in: a co-author from AACR is connected to a CMC advisor in Torres’s network. Crescent is presenting preclinical ADC data at AACR 2026 (April) and evaluating vendor partnerships through Q2.

Lead through the chain: “Rachel, [CMC Advisor] mentioned you’re building out analytical infrastructure for the ADC program. As you evaluate vendors ahead of AACR, happy to share how similar-stage biotechs have approached it.”
Key Contact
Rachel Torres, Head of CMC
You ▶ AACR Co-Author ▶ CMC Advisor ▶ R. Torres 3rd
LinkedIn •••••• r.torres@••••.com NEW
Pipeline & Timing
Lead candidate: ADC targeting Nectin-4, IND cleared Jan 2026
AACR 2026: Presenting preclinical ADC data (April)
Vendor evaluation: Active through Q2 2026, no incumbent
Open Roles (LinkedIn)
Sr. Analytical Scientist, Biologics — Waltham, MA · Posted 2 weeks ago
Analytical Scientist, CMC — Waltham, MA · Posted 3 weeks ago
Associate Scientist, Bioanalytical — Waltham, MA · Posted 1 month ago
Target HCP / KOL

Dr. Sarah Chen, MD, PhD

VP, Translational Medicine • Top-20 Biopharma
ASCO 2026 Speaker · May 2026 3 Publications · 2025–2026 KOL · Advisory Board
Why Now
Presenting on translational biomarker strategies at ASCO 2026 (May, Chicago). Published 3 papers since March 2025 on companion diagnostics for ADC therapies. Most recent (Dec 2025, JCO) cited your competitor’s assay platform, but flagged limitations in clinical sensitivity.
Opportunity Size
M Platform evaluation, potential site-wide adoption
Your Play
You’re a direct LinkedIn connection to Dr. Chen. She’s presenting at ASCO in May and chairing a companion diagnostics symposium at AACR in April—both are pre-conference outreach windows. Her most recent JCO paper cited your competitor’s assay platform but flagged limitations in clinical sensitivity—exactly what your platform solves.

Lead with the research: “Sarah, your JCO paper on companion diagnostic sensitivity for ADC patient selection was excellent. You flagged the exact limitation we’ve helped 3 oncology teams solve this year. I see you’re presenting at ASCO in May—would love to connect beforehand.”
Key Contact
Dr. Sarah Chen, MD, PhD, VP, Translational Medicine
You ▶ Dr. Chen 1st
LinkedIn •••••• s.chen@••••.com IN CRM
CRM History
Closed-lost: $45K opp from 18 months ago (lost to [competitor] on sensitivity specs). Demo completed, champion was her direct report. Contact record exists but marked inactive. Last email opened 6 months ago.
Professional Network
MD (Stanford), PhD Immunology (MIT). 15 years spanning clinical practice and biopharma R&D. Previously at Regeneron (Associate Medical Director) and Genentech (Clinical Scientist). Active KOL in oncology. Advisory board for 2 FDA-approved therapies. Publishes in NEJM, JCO, and Nature Medicine.
Deep Dive

Persona-mapped dossiers on priority accounts, competitive landscape, named stakeholders, and specific hooks for each.

Deep Dive

Full Account Dossier: Regeneron Pharmaceuticals

Priority account selected by your sales leader. 9 sites across 2 countries, 18 new Phase 3 studies planned for 2026, 30+ named personas mapped by department and influence level, competitive landscape across three bispecific franchises, and entry points tied to a $2B greenfield build, 2,000+ new hires, and triple product launch.
Account Snapshot
$14.3B
FY 2025 Revenue
$5.9-6.1B
2026 R&D Guidance
9 Sites
+ 1 Greenfield
18
New Phase 3 Studies (2026)
VelociSuite Scaling $2B Greenfield Build Triple Bispecific Launch Cell Medicines R&D Digital Transformation $3B FUJIFILM Partnership
Strategic Priorities
● R&D / Discovery ● Clinical ● Manufacturing ● Digital / IT ● Emerging
Site Opportunity Map
Persona Map (30+ Contacts)
Recommended Outreach
Persona-specific hooks – not templates, but angles that connect account initiatives to your product’s value.
Manufacturing / CMC Leader
“Saratoga Springs – spec equipment into the design phase”
$2B greenfield site with no incumbent vendors in any equipment category. Procurement director for capital equipment hiring now. 1,000 jobs planned over 3-5 years. Position during buildout before vendor lock-in – once equipment is spec’d into facility design documents, switching costs become structural.
R&D / Discovery Leader
“50+ new scientists onboarding at Tarrytown”
VelociSuite platform scaling to support 18 new Phase 3 studies planned for 2026. Instrument and reagent needs for an onboarding wave of 50+ scientists across antibody discovery, flow cytometry, and bioassay. Engage discovery leadership before new scientists arrive and default to whatever is already on the bench.
Clinical / Translational Leader
“Three bispecific franchises scaling simultaneously”
Companion dx needs for Lynozyfic (launched) + fianlimab (Phase 3) + odronextamab (EU-approved) across three different tumor types. Biomarker expansion across 30+ candidates. Clinical ops expanding at Armonk with 18 new Phase 3 studies planned for 2026. Three separate buying cycles running in parallel – each franchise has its own budget and timeline.
Competitive Landscape
Franchise Regeneron Key Competitors Market Signal
Myeloma (BCMA) Lynozyfic (approved) J&J Tecvayli, Pfizer Elrexfio Regeneron claims best efficacy
Lymphoma (CD20) Odronextamab (EU-approved as Ordspono) Roche Columvi, AbbVie Epkinly 2nd US CRL (mfg) – competitors already launched
Melanoma (LAG-3) Fianlimab + Libtayo (Phase 3) BMS Opdualag Early data suggests superior efficacy
Manufacturing $7B+ expansion across 5 sites – No incumbents at greenfield sites
Recommended Strategy
Lynozyfic launched, fianlimab Phase 3 data imminent, odronextamab already approved in EU – three bispecific franchises driving simultaneous clinical ops, bioanalytical, companion diagnostics, and manufacturing expansion. Greenfield sites (Saratoga Springs, Cambridge/Seattle Cell Medicines) have no incumbent vendors in any equipment category. Engage procurement during buildout – once equipment is spec’d into facility design, switching costs become structural.
Why Deep Dives Matter
Monthly reports surface the signal. Deep dives turn it into a strategy. Your rep walks into this account knowing who to call, what to say, and where the competitor is vulnerable – not just that the company is growing.
What’s Included
▶ 30+ named personas with titles, LinkedIn, email, and entry angles
▶ Competitive landscape map with contract timing and satisfaction signals
▶ Facility-level opportunity breakdown
▶ Outreach hooks tailored to each persona type
▶ Every claim sourced – SEC filings, job postings, conference proceedings, press releases
Included in Every Tier
PoC: 1 deep dive (you pick the account)
Standard: 1 deep dive per month
Premium: 3 deep dives per month
Sources Cross-Referenced
SEC 10-K LinkedIn Press Releases Conference Programs (ASMS, CASSS) Job Boards Clinical Trial Registries Patent Filings Partnership Announcements TheOrg
Conference Intelligence ADD-ON

Conference-matched targets with day-by-day action plans and prioritized booth schedules for your team.

revenue-catalyst-conference-intel-aacr-2026.htmlrc-conf-intel-aacr-2026.html
RevenueCatalyst
Conference Intelligence — AACR 2026
229 Posters 31 Talks 2 Competitors 260 Contacts
Summary
Sun 4/19Sun
Mon 4/20Mon
Tue 4/21Tue
Wed 4/22Wed
Competitive
Contacts
Monday, April 20, 9:00 AM – 5:00 PM
Filter
Sort
58 Posters 8 Talks 2 Competitors 69 Contacts
Posters 58
Top 2 of 58 by fit score
1 Abs 2606  ·  Bd 25  ·  Sec 46  ·  Mon 9:00 AM
94% FIT CA
A liquid biopsy assay of estrogen receptor activity predicts response to giredestrant in ER+/HER2− advanced breast cancer
Genentech × Precede Biosciences — A. Collier / C. Barrett  ·  South San Francisco, CA & Boston, MA
Digital PCR Liquid Biopsy Epigenomics Multiplex Genomics ctDNA / Chromatin +2 more
Why Now
Genentech’s giredestrant (oral SERD, Phase 3 ER+/HER2− aBC) biomarker program leans on Precede Biosciences’ PERDI — a multiplex plasma-chromatin readout across enhancer, promoter, and DNA methylation features. PERDI runs alongside a commercial ctDNA CDx for baseline ESR1 mutation calls. Pharma × biotech co-development, mid-Phase 3, actively productizing.
Drives 94% FIT = Phase 3 SERD biomarker + Pharma×biotech co-dev + Multiplex chromatin readout
Your Play
Dual-account play in one poster. Genentech side: pitch your digital PCR workflow for orthogonal ESR1 mutation calls and ER-pathway PD readouts feeding the confirmatory-trial expansion. Precede side: emerging biotech scaling across more pharma collaborations — a high-plex digital PCR workflow is the natural orthogonal validator for enhancer-call confirmation as patient volumes ramp.
Presenting Author (Genentech)
Ann E. Collier, Scientist — Oncology Biomarker Development, Genentech
You ▶ M. Ramirez (Bay Area FAS) ▶ A. Collier 2nd
LinkedIn ••••• collier.a@ •••• .com IN CRM
Senior Author / Assay Lead (Precede Biosciences)
Carl J. Barrett, Scientific Lead — Precede Biosciences, Boston
You ▶ D. Nguyen (Boston FAS) ▶ C. Barrett 2nd
LinkedIn ••••• cbarrett@ •••• .com NEW
2 Abs 3111  ·  Bd 11  ·  Sec 17  ·  Mon 2:00 PM
91% FIT OH
Pancreatic cancer cells elevate NAD+ production in response to nutrient limitation and chemotherapeutic stress
Case Western Reserve University — F. Nakazzi / J. Winter  ·  Cleveland, OH
Analytical Instruments Reagents & Consumables Protein Analysis Metabolomics +4 more
Why Now
The Winter lab is running a multi-front PDAC program — Western blot is the core readout for NAD+ synthesis enzyme expression across PANC-1, MIA PaCa-2, and BxPC-3 lines, plus in vivo xenograft and C57BL/6 mouse studies. Winter is senior author on AACR 2026 poster #512 (wtIDH1/PARP synthetic lethality) and minisymposium #6805 (ketogenic diet), plus co-author on poster #3799 (HER3 immunotherapy) — all four studies lean on WB readouts.
Drives 91% FIT = 4× AACR posters on WB + Multi-line PDAC + Scale-up signal
Your Play
Four concurrent AACR posters sharing one WB workflow — classic scale-up signal. Ask about lane count per week across the PDAC pipeline and offer a multi-gel throughput demo.
Presenting Author
F. Nakazzi, Graduate Researcher (Biochemistry, Case Western)
You ▶ M. Zarei ▶ F. Nakazzi 2nd
LinkedIn ••••• fxn@ •••• .edu NEW
Senior Author
Dr. J. Winter, PI, UH Cleveland Medical Center
You ▶ J. Winter 1st
LinkedIn ••••• j.winter@ •••• .edu IN CRM
View all 58 posters
Talks 8
Top 2 of 8 by fit score
3 Major Symposium SY27Maj. Symp.  ·  Ballroom 20 AB (Upper Level)BR 20 AB  ·  Mon 12:55 PM
94% FIT NY
BMAL2 is a KRAS-driven master regulator of hypoxic adaptation in pancreatic ductal adenocarcinoma
Columbia University Irving Medical Center (Olive Lab) — A. Curiel Garcia  ·  New York, NY
Live Cell Analysis Metabolic Assays Cellular Respiration Cancer Research +2 more
Why Now
Olive lab’s 242-PDAC regulatory-network analysis identified BMAL2 as the top KRAS-driven metabolic regulator — and their Seahorse data explicitly shows BMAL2 loss drops OCR. Talk slot inside the high-profile RAS Major Symposium signals this is their headline metabolism story for 2026, and they’re leaning on endpoint Seahorse reads to characterize a transient hypoxia-adaptive state.
Drives 94% FIT = Seahorse OCR phenotype + RAS Symposium headline + Kinetic gap
Your Play
Catch Curiel Garcia after the talk, then request a lab visit with Olive — the abstract calls out OCR drops as the key phenotype, which is exactly what continuous-read monitoring captures in kinetic detail. Bring a BMAL2 KO time-course overlay as the leave-behind.
Presenting Author
A. Curiel Garcia, Postdoctoral Researcher (Olive Lab)
You ▶ M. Badgley ▶ A. Curiel Garcia 2nd
LinkedIn ••••• ac4567@ •••• .edu NEW
Senior Author
Dr. K.P. Olive, Associate Professor / PI, Columbia HICCC
You ▶ K.P. Olive 1st
LinkedIn ••••• kpo2001@ •••• .edu IN CRM
6 Minisymposium MS.ET06.01Minisymp.  ·  Room 28 (Upper Level)Rm 28  ·  Mon 4:05 PM
87% FIT VT
PRX3 deletion impairs mitochondrial bioenergetics in mesothelioma — preclinical anchor for RSO-021 first-in-human trial
University of Vermont (Cunniff Lab) — V. Gibson  ·  Burlington, VT
Live Cell Analysis Bioenergetics Cellular Respiration Translational Research +3 more
Why Now
Cunniff lab’s PRX3 KO data — OCR drops, ECAR drops, mROS rises — is the preclinical spine of the RSO-021 Phase 1 trial (NCT05278975, 67% disease control at 12 weeks). Cunniff sits on RS Oncology’s board, so this bioenergetics story has direct commercial pull — and Phase 2 dosing decisions will lean on richer kinetic OCR/ECAR data.
Drives 87% FIT = Phase 1 trial spine + Board seat pull + Phase 2 kinetic upgrade
Your Play
Lead with the Phase 2 transition — continuous OCR/ECAR kinetics give them a richer dose-response window than endpoint Seahorse reads. Cunniff’s RS Oncology board seat is the commercial lever — pitch Gibson on a co-authored methods note tied to the RSO-021 translational package.
Presenting Author
V. Gibson, Graduate Researcher (Cunniff Lab)
You ▶ K. Butnor ▶ V. Gibson 2nd
LinkedIn ••••• v.gibson@ •••• .edu NEW
Senior Author
Dr. B. Cunniff, PI / RS Oncology Board & Stock
You ▶ B. Cunniff 1st
LinkedIn ••••• brian.cunniff@ •••• .edu IN CRM
View all 8 talks
Competitors 2
Showing 1 of 2
2 Bd 8  ·  Sec 12  ·  Mon 9:00 AM
CA
[Company X] presenting automated capillary Western for clinical biomarker validation
2 of your target accounts are co-authors  ·  Mon 9 AM (Board 8), Tue 2 PM (Board 12)
Clinical Diagnostics Bioanalytical Protein Analysis Automation +2 more
Why Now
[Company X] announced a 40% price cut on Cascade-96 at their AACR press release (3d ago). Already in active evaluation at UCSF and Dana-Farber — both in your Q2 pipeline. Poster reframes capillary format as “clinical-grade throughput.”
Your Play
Visit Board 8 Monday 9 AM before the [Company X] team arrives — counter Cascade-96 pricing with your 18-month TCO (consumables 35% cheaper, throughput 2x). Leave the Penn Med validation one-pager (0.7% CV vs. their published 2.1%) with the two target-account co-authors.
View all 2 competitors
Mon 4/20 Walking Route — Top 5 Poster Stops
Prioritized by FIT Score
Poster Sec 1–11 Poster Sec 12–19 Poster Sec 28–37 Poster Sec 20–27 Poster Sec 46–55 Poster Sec 38–45 Johnson & Johnson Merck Eli Lilly Pfizer Oncology AstraZeneca REGISTRATION ENTRANCE 1 ENTRANCE 2 ENTRANCE 3 SAN DIEGO CONVENTION CENTER HALL S HALL A START YOUR BOOTH 1 9 AM 2 10:30 AM 3 12:00 PM 4 2 PM 5 3:30 PM Suggested Route
Your Booth Top 5 Poster Stops Competitor Booths (off-route)
Stepping stones (You ▶ J. Park ▶ L. C-C) and CRM match status ( IN CRM) for every contact are unlocked with a Sales Intel Agents subscription. Sales Intel subscribers also save 20% on Conference Intel packages.

Sample cards based on real agent deliveries. Names and details are illustrative. Your cards are tailored to your products, territory, CRM, and ICP. Every card cross-references your CRM, external signals, your reps’ network, and your sales playbook. That’s what makes it actionable, not just informational.

Why Now

Commercial Teams Betting on AI Agents Are Pulling Ahead.

BCG reports AI leaders achieve 1.7x the revenue growth of laggards, and the gap is widening quarterly.

Your team is manually tracking signals across dozens of sources

AI agents monitor everything. Overnight.

Regulatory approvals, SEC filings, clinical trials, funding rounds, executive moves, job postings, press releases, product launches, conference announcements, social media, and partnership signals. Filtered to your territory before your first meeting.

Result: 2,400 evidence-matched leads for a single client

Salesforce reports 30% of HCLS sales effort fails to target the intended decision maker or leverage the appropriate messaging

Science-matched targeting changes the math

Prospects matched to their own publications, conference talks, and research grants. Every touchpoint references something real, not a template. Industry average cold email open rate is ~23%. Ours hit 56%.

Result: 56% open rate • 2.4x industry average

9% of life sciences execs see real returns on AI. The other 91% are still experimenting. We build the agents that put you in the 9%.

The window for first-mover advantage is now

McKinsey found only 6% of organizations capture real value from AI. The difference isn’t the technology. It’s having operators who know your workflows build the system. We’ve done it 6 times in HCLS and counting.

Result: 43 new opps in 2.5 months from a standing start

Sources

BCG: AI Leaders Outpace Laggards (2025) McKinsey: State of AI (2025) Deloitte: Life Sciences Outlook (2026) Salesforce: HCLS AI Survey (2025) Bain: Commercial AI Winners (2025) ZS: Scaling AI in Pharma (2026)

What We Build, and What It Costs

Transparent pricing. Every engagement starts with your team’s actual needs.

Sales Intelligence Agents

Expansion signals, net-new prospects, account deep dives, and competitive landscape – matched to your ICP and sales territories. Live in 2–3 weeks.

What You Get

  • Expansion signals in existing accounts + ranked net-new prospects matched to your ICP
  • Named decision-makers with LinkedIn, email, entry angles, and CRM status
  • Account deep dives: competitive landscape, persona mapping, conference intel, and outreach hooks
  • Branded, territory-specific HTML reports – forward to reps or print for team meetings

Why This Isn’t DIY (Your In-House LLMs)

  • 25+ live data sources refreshed monthly – government & regulatory APIs, job intelligence platforms, industry news feeds, financial data, and AI-powered deep research – not months-old training data
  • Dedicated fact-check pass on every figure, name, and company detail – no hallucinated contacts
  • Cumulative memory across reports – each month builds on the last instead of starting from scratch
  • Your install base cross-referenced on every run – expansion signals are real customers, net-new prospects aren’t
Protein Analysis Company: Expansion intelligence across 5 key accounts, 7 ranked net-new prospects matched to ICP, and a full account dossier with named personas and outreach hooks. Delivered in one session.
Pharma Field Team: Territory-level competitive intelligence: HCP targets, key account signals, and KOL activity. Replacing hours of weekly manual research with overnight autonomous delivery.
One-Time Charge

Managed Intelligence – Standard

$3,500/mo$33,600/yr *
Per product linePer product line – $2,800/mo effective – Save 20%
  • Monthly tabbed report with per-rep territories
  • 1 account deep dive per month (you pick)
  • Expansion signals + net-new prospects
  • Tuned monthly from your feedback – gets smarter over time
YOUR LIFT: NEAR ZERO
Share customer list, confirm priority account, forward reports to reps. No IT, no security review. Zero footprint on your systems.

Managed Intelligence – Premium

$5,000/mo$48,000/yr *
Per product linePer product line – $4,000/mo effective – Save 20%
  • Everything in Standard
  • 3 account deep dives per month (2 additional)
  • Monthly strategic review call (30 min)
  • LinkedIn network matching (optional) – see which contacts your reps already know
YOUR LIFT: NEAR ZERO
Same as Standard, plus 30 min/month strategic review. No IT, no security review. Zero footprint on your systems.
* Tiered volume pricing available — rates drop as you add product lines. New tiers, new savings.
Let’s Scope Your Plan →
One-Time Charge

Build + Transfer

$25,000 – $35,000
Per product line + $1,500/mo advisory
  • Full agent stack on your infrastructure
  • Team training, docs, and IP transfer
  • Advisory retainer for ongoing tuning
  • You own the agents and data pipeline
YOUR LIFT: SIGNIFICANT
IT involvement required. Your team maintains infrastructure, API keys, and model costs.
* Tiered volume pricing available — rates drop as you add product lines. New tiers, new savings.
Let’s Scope Your Plan →
Start with a $2,500 Proof of Concept
Full Standard deliverable delivered within a week. Your team works the intel for the rest of the month. If it drives action, the $2,500 is credited toward your subscription. If not, you keep the report.
Get Started

Conference Intelligence Agents

Your team shows up with a plan, not a program book. Day-by-day poster hit lists, competitive intel, and marketing mailer content – built by AI, curated by HCLS operators.

What You Get

  • AI scrapes every poster abstract, matches against your products and target accounts, and ranks the top conversations your reps should have – organized by day and session
  • Named presenters with institution, LinkedIn profile, and a custom outreach hook for each poster
  • Competitive intelligence overlay: which competitors are presenting, which of your accounts appear on their posters
  • Pre-conference mailer content for marketing: poster-specific outreach copy that drives qualified booth traffic
  • Session priorities and talk tracks aligned to your competitive landscape

What This Replaces

  • Manual program review (8-15 hours of rep time, finds 5-10 posters, misses the other 20)
  • Badge scanning and attendee lists (captures who stopped by, not who should have)
  • Generic pre-conference mailers (“Visit us at booth 1234” = noise)
Western Blot Manufacturer: 229 poster abstracts scraped from AACR 2026 in under 15 minutes. Top 10 curated with named contacts, outreach hooks, and a day-by-day schedule. Full competitive overlay included.

Single Conference

$1,500
Per product line
  • Full action plan for one conference
  • Poster hit list + named contacts
  • Competitive intel overlay
  • Marketing mailer content
YOUR LIFT: NEAR ZERO
Share your product line, target accounts, and booth number. We deliver the action plan before your team lands.

3-Pack

$3,750
Per product line – Use within 12 months
  • Everything in Single Conference
  • Cover your top 3 conferences this year
  • Consistent formatting across events
  • Cumulative competitive tracking
YOUR LIFT: NEAR ZERO
Same as Single. We build institutional memory across your conferences – patterns compound.

5-Pack

$5,000
Per product line – Use within 12 months
  • Everything in Single Conference
  • Full-year coverage for heavy conference teams
  • Priority scheduling during peak season
  • Cross-conference trend analysis
YOUR LIFT: NEAR ZERO
Share your annual conference calendar at the start. We handle the rest.
Sales Intel Agents Subscribers Save 20%
Active Managed Intelligence subscribers (Standard or Premium) receive 20% off any conference package.
Get Started

Prospecting

Find the right people, at the right companies, at the right time, and get your reps in front of them.
  • Prospects matched to their own publications, conference talks, grants, and research, so every touchpoint references something real, not a template
  • KOL identification, key account mapping, and HCP targeting using NPI databases, SciLeads, and your existing data subscriptions
  • Multi-channel campaigns across email, LinkedIn, and phone, built on proven HCLS outreach methodology
  • Real-time dashboards for engagement tracking, MQL/SQL routing, and pipeline visibility
  • Full infrastructure setup: domain warm-up, deliverability optimization, and sequencing tools so you launch clean
VC-Backed Single-Cell Biotech: 16,000 leads, 43 new opportunities, and 90 qualified MQLs in 2.5 months. Sales cycles under 60 days.
Protein Analysis Company: 2,400 publication-matched leads, 56% open rate (2.4x industry average), and 4 orders won from a single cold email campaign.
$10K – $25K

Project-based. Scoped to your ICP, channels, and campaign goals.

Let’s Scope It

Demand Generation

Campaigns built for scientific buyers: educate researchers and convert them into pipeline.
  • Content and messaging strategy designed for technical audiences: application notes, workflow guides, and campaign pages that speak the language of your buyers
  • Pre- and post-conference outbound campaigns tied to specific events (AACR, ASHG, SLAS, ASCO, and beyond)
  • Google and LinkedIn advertising optimized for scientific search terms and researcher audiences
  • SEO and website optimization: landing pages, forms, CTAs, and conversion tracking built for how scientists actually browse
  • Marketing automation setup and optimization (HubSpot, Marketo, Pardot): lead scoring, nurture sequences, and MQL routing
  • Account-based marketing campaigns targeting named accounts with personalized content
Life Science Tools Company: 6 campaign pages drove 19.2% of total website traffic with 79% new users.
Project-based or fractional retainer

Scoped to your campaigns, channels, and growth targets.

Let’s Scope It

Sales Operations

Pipeline visibility and forecasting your leadership can actually trust, built by people who’ve used these dashboards to run territories.
  • Full CRM build, migration, and automation: Salesforce, HubSpot, Veeva, or Dynamics
  • Forecasting dashboards tied to monthly goals with commit, best case, and pipeline views
  • Territory planning, lead scoring, and account segmentation
  • Sales process documentation, onboarding playbooks, and rep ramp programs
  • CS and renewal dashboards: track customer health, expansion signals, and churn risk
  • Reporting and analytics in Power BI, Tableau, or native CRM dashboards
AI Medical Scribe Platform: Built dashboards for Sales, Marketing, and Executive teams. Forecasting time cut from 2 days to 30 minutes per territory manager. First-ever visibility into deal velocity.
Project-based or fractional retainer

Scoped to your CRM, pipeline, and reporting needs.

Let’s Scope It

Client Results

Outcomes from HCLS commercial teams. From first engagement to measurable impact.

VC-Backed Single-Cell Biotech

Sales Pipeline from Zero to 43 Opportunities

43 Qualified Opps 2x $100K Orders in 60 Days In 2.5 Months
“Created a significant sales funnel from scratch, in a scalable and trainable way which allowed our team to take over and continue growing it independently.”
– Co-Founder & CSO
Hover front for stats
AI Medical Scribe Platform

From No CRM to Full Pipeline Visibility

Deal Velocity Tracking Revenue Forecasting 3 Team Dashboards
“Gave us a foundation from which to measure performance, in general and more systematically, which helped us understand foundational dynamics with regard to sales performance, deal velocity, and forecasting.”
– SVP & Head of Sales
Hover front for stats
Microfluidic Flow Cytometry

40% Revenue Growth, 3 Sales Hires Onboarded

40% YOY Growth 3 Reps Hired & Trained On Scope & Budget
“Best in class for our small size company. On scope, on time, on budget.”
– VP Commercial
Hover front for stats
Protein Analysis Technology

56% Open Rate, 2.4x Industry Average

56% Open Rate 2,400 Publication-Matched Leads 4 Orders Won
2,400 validated leads from evidence-matched scientific publications. 5-email sequence ramped to 100 daily sends. 4 order submissions including 1 new customer.
– Co-Founder & CEO
Hover front for stats
Life Science Tools Company

6 Campaigns Drove 19.2% of All Website Traffic

3,246 Campaign Sessions 79% New Visitors 6 Campaign Pages
6 linked campaign pages driving 3,246 sessions. Top performer: Live Cell Painting (1,252 sessions). CTA pages: Shop (614 sessions), Contact Us (204 sessions).
– Head of Marketing
Hover front for stats

The Team

Operators who’ve carried the bag, managed the territory, and built the systems.

Trey Knollman - Partner, Revenue Catalyst

Trey Knollman

Founder & AI Agent Architect
Seattle, WA

18 years inside HCLS companies spanning bench to boardroom. Scientist at Thermo Fisher, then commercial leader through three acquisitions (Essen BioScience, IntelliCyt, Amplion) and an IPO (IsoPlexis). Built and led teams that hit 147% of quota, drove 40% YOY revenue growth, and took products from zero to market across flow cytometry, single-cell, genomics, and diagnostics.

Flow cytometry, single-cell analysis, genomics/proteomics, diagnostics, digital health, SaaS
LinkedIn →
Sohiel Memarsadeghi - Partner, Revenue Catalyst

Sohiel Memarsadeghi

Partner & Technical Architect
San Francisco, CA

Biomedical engineer with 20 years developing and commercializing analytical technologies in biotech and drug discovery. Built four instrument platforms from concept to market — IncuCyte, FLIPR, IonWorks HT, and NX One — spanning engineering, R&D, and technical sales at Essen BioScience (acquired by Sartorius for $320M).

Live-Cell Analysis, GPCR screening, high-throughput electrophysiology, microfluidics
LinkedIn →

Frequently Asked Questions

Common questions from HCLS commercial leaders evaluating AI agents and revenue operations.

AI agents are autonomous software systems that monitor market signals overnight – FDA approvals, SEC filings, clinical trial milestones, funding rounds, hiring surges, conference announcements, and more – then enrich and score those signals against your ICP, territory, and CRM data. By morning, your reps get actionable intel cards with named decision-makers, outreach hooks, and recommended next steps. Unlike traditional sales tools that require manual research, AI agents work 24/7, cross-reference dozens of sources, and deliver ready-to-act intelligence tailored to your commercial processes.
Revenue Catalyst provides AI agents and full-service revenue operations for healthcare and life sciences commercial teams. Sales Intelligence Agents deliver territory-specific signals, verified contacts, competitive intel, and outreach hooks in monthly HTML reports – zero IT required. Conference Intelligence Agents prepare teams for scientific conferences like AACR, ASCO, ASH, and PEGS with day-by-day poster hit lists, named presenters, and competitive overlays. Prospecting services include science-matched targeting, KOL identification, and multi-channel campaigns with end-to-end infrastructure. Demand Generation covers conference campaigns, paid media, SEO, and marketing automation with lead scoring. Sales Operations includes CRM optimization, revenue forecasting dashboards, territory planning, and pipeline analytics. Every service is built by HCLS operators with 50+ years of combined experience spanning IC to VP roles across sales, marketing, and customer success.
Our Sales Intelligence agents follow a 5-stage pipeline: (1) data collection from 25+ sources including regulatory databases, job boards, industry news feeds, financial filings, and clinical trial registries; (2) signal processing that filters thousands of data points through your ICP definition, install base, and territory map; (3) three parallel research agents running simultaneously – expansion signals, net-new prospects, and a deep account dossier – each with domain-specific prompting built on 50+ years of HCLS experience; (4) a dedicated fact-check agent that independently verifies every figure, contact, and company detail against public sources; and (5) territory-ready HTML reports tabbed by rep, with a worldwide view for sales leadership. One client went from zero pipeline to 43 qualified opportunities in 2.5 months.
Every engagement starts with a $2,500 Proof of Concept – a full report delivered within a week so your team can evaluate real output, not a demo. If you continue, the $2,500 is credited toward your subscription. Managed Intelligence starts at $3,500 per product line per month, with graduated volume discounts for companies with multiple product lines. Annual commitments save 20%. Build + Transfer is $25,000–$35,000 per product line (one-time) plus $1,500/month advisory for teams that want to own the agent stack. No lock-in contracts.
Conference Intelligence Agents prepare your team for scientific conferences like AACR, ASCO, ASH, ASHG, SLAS, and PEGS. Our AI scrapes every poster abstract from the conference proceedings, matches them against your product line and target accounts, and delivers a day-by-day action plan with a ranked poster hit list, named presenters with outreach hooks, competitive intelligence (which competitors are presenting and where your accounts overlap), and pre-conference mailer content for your marketing team. The result: your reps show up knowing exactly where to be and what to say, instead of scanning the program book in the hotel lobby. Pricing starts at $1,500 per product line per conference, with 3-pack (save 17%) and 5-pack (save 33%) options. Volume discounts apply for companies covering multiple product lines. Active Sales Intel subscribers receive 20% off any conference package.
For Managed Intelligence, there is zero integration required – we cross-reference your install base and CRM exports, then deliver standalone HTML reports your team can open anywhere. No IT involvement, no security review, no software to install. For Build + Transfer clients who want full integration, our agents connect to Salesforce, HubSpot, Veeva, and Dynamics 365, plus your existing data subscriptions. Signals are cross-referenced against your CRM history so reps see open opportunities, stalled deals, and past interactions alongside new market intelligence. Build + Transfer deploys on your VPC or a dedicated single-tenant server with end-to-end encryption.
Traditional sales automation (sequences, cadence tools, CRM workflows) executes predefined steps. AI agents reason autonomously: they discover signals your team did not know to look for, cross-reference multiple data sources in real time, and generate personalized outreach anchored to each prospect’s publications, conference talks, or regulatory milestones. The result is outreach that references something real – not a template – which is why our clients see 56% email open rates versus the 23% industry average.
Your first report is delivered within a week of kickoff – no integration, no onboarding delays. From there, the agent gets sharper as it learns your ICP, install base, and territory structure. One analytical instruments client went from zero outbound pipeline to 43 qualified opportunities in 2.5 months. A protein analysis company saw a 56% cold email open rate within the first campaign cycle. Because the agent runs autonomously overnight, your team starts every week with fresh, territory-ready intelligence instead of spending hours on manual research.
We have built and run commercial teams in analytical instruments, flow cytometry, single-cell analysis, genomics, proteomics, diagnostics, digital health, pharma services, and medtech – at companies including Thermo Fisher, Sartorius, Bio-Rad, and multiple venture-backed startups. That operating experience is what makes the intelligence useful. We know which FDA approval is a buying signal versus noise, which conference talks indicate budget authority, and which hiring patterns signal expansion. The agents are prompted with that context, not generic templates.
Every report passes through a dedicated fact-check agent before delivery. This verification agent independently cross-checks every contact name, title, company detail, and market claim against public sources – SEC filings, FDA databases, ClinicalTrials.gov, LinkedIn, and company websites. Contacts include source tags showing exactly where each data point originated. If a claim cannot be verified, it gets flagged or removed – never guessed. On top of that, our team reviews every report with the same judgment we used managing territories and running commercial teams. We catch things a generic system would miss because we have sold into these accounts ourselves.

Let’s Talk

Whether you need an AI agent, a full commercial engine, or want to explore what’s possible, start here.

Start a Conversation →

Let’s Talk

Tell us a bit about your team and we’ll reach out within 24 hours.